News


( Last Updated : March 7, 2015)

November 26, 2020
Voretigene neparvovec (Luxturna) is the first gene therapy evaluated through the CADTH reimbursement review process CADTH recommends reimbursement with conditions, including a price reduction, and offers advice on implementing the recommendation On November 16, CADTH recommended that Canada’s…
November 25, 2020
Did you miss some of the great live sessions during the 2020 Virtual CADTH Symposium? Great news — our plenary and concurrent sessions are now available for on-demand viewing on the Symposium website. In more great news, we’ve added 30 new pre-recorded sessions that will bring you fresh insights…
November 16, 2020
After a Breakout Year for Digital Health, What’s Next? This week, I’m proud to join Canadian health system leaders in celebrating Digital Health Week — a time to recognize how digital health is transforming the delivery of care. When I think of the changes brought about by this pandemic, the “…
November 9, 2020
Today CADTH presented Recognition Awards to two scientists to honour their exceptional contributions to the field of health technology assessment (HTA) — one as a pioneer who has pushed the boundaries of economic evaluation in child health and the other as a rising star who is advancing the use of…
November 4, 2020
Beginning on Thursday, November 5th, we are changing our email notification process for all CADTH reimbursement reviews. The following milestones in all reimbursement reviews will now be communicated once per week in the new CADTH Weekly Summary: open calls for patient input and clinician input…